538 related articles for article (PubMed ID: 29051062)
1. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
3. Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment.
Singh A; Shafi S; Upadhyay T; Najmi AK; Kohli K; Pottoo FH
Curr Top Med Chem; 2020; 20(20):1839-1854. PubMed ID: 32579503
[TBL] [Abstract][Full Text] [Related]
4. The Application of Pre-clinical Animal Models to Optimise Nanoparticulate Drug Delivery for Hepatocellular Carcinoma.
Zhang Z; Song L; Guo J
Pharm Nanotechnol; 2018; 6(4):221-231. PubMed ID: 30277174
[TBL] [Abstract][Full Text] [Related]
5. Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma.
Zhao H; Wu M; Zhu L; Tian Y; Wu M; Li Y; Deng L; Jiang W; Shen W; Wang Z; Mei Z; Li P; Ran H; Zhou Z; Ren J
Theranostics; 2018; 8(7):1892-1910. PubMed ID: 29556363
[No Abstract] [Full Text] [Related]
6. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future.
Zhang X; Ng HLH; Lu A; Lin C; Zhou L; Lin G; Zhang Y; Yang Z; Zhang H
Nanomedicine; 2016 May; 12(4):853-869. PubMed ID: 26772424
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
8. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response.
Burkhart RA; Ronnekleiv-Kelly SM; Pawlik TM
Surg Oncol; 2017 Jun; 26(2):138-145. PubMed ID: 28577719
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic targets and predictive markers for hepatocellular carcinoma.
Chan SL; Chan AW; Yeo W
Expert Opin Ther Targets; 2015 Jul; 19(7):973-83. PubMed ID: 25910512
[TBL] [Abstract][Full Text] [Related]
10. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.
Cai Y; Xu Y; Chan HF; Fang X; He C; Chen M
Mol Pharm; 2016 Mar; 13(3):699-709. PubMed ID: 26808002
[TBL] [Abstract][Full Text] [Related]
11. Stepwise targeting and responsive lipid-coated nanoparticles for enhanced tumor cell sensitivity and hepatocellular carcinoma therapy.
Li Y; Miao Y; Chen M; Chen X; Li F; Zhang X; Gan Y
Theranostics; 2020; 10(8):3722-3736. PubMed ID: 32206118
[No Abstract] [Full Text] [Related]
12. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention.
Tian M; Shi Y; Liu W; Fan J
Sci China Life Sci; 2019 Sep; 62(9):1138-1143. PubMed ID: 31119560
[TBL] [Abstract][Full Text] [Related]
13. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
Nasr M; Nafee N; Saad H; Kazem A
Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
[TBL] [Abstract][Full Text] [Related]
14. Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma.
Teran-Saavedra NG; Sarabia-Sainz JA; Silva-Campa E; Burgara-Estrella AJ; Guzmán-Partida AM; Ramos-Clamont Montfort G; Pedroza-Montero M; Vazquez-Moreno L
Molecules; 2019 Apr; 24(7):. PubMed ID: 30970533
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in hepatocellular carcinoma-targeted nanoparticles.
Liu X; Bai Y; Zhou B; Yao W; Song S; Liu J; Zheng C
Biomed Mater; 2024 May; 19(4):. PubMed ID: 38697209
[TBL] [Abstract][Full Text] [Related]
16. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab')
Jin C; Bai L; Lin L; Wang S; Yin X
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1076-1084. PubMed ID: 28776396
[TBL] [Abstract][Full Text] [Related]
18. Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma.
Zamboni CG; Kozielski KL; Vaughan HJ; Nakata MM; Kim J; Higgins LJ; Pomper MG; Green JJ
J Control Release; 2017 Oct; 263():18-28. PubMed ID: 28351668
[TBL] [Abstract][Full Text] [Related]
19. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
20. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
Xiong Q; Cui M; Bai Y; Liu Y; Liu D; Song T
Colloids Surf B Biointerfaces; 2017 Jul; 155():93-103. PubMed ID: 28411478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]